A Network Genomic Risk Assessment of the Electronic Medical Records and Genomics

Overview

About this study

The electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment Study is a multisite study funded by the National Human Genome Research Institute (NHGRI) to investigate the clinical utility of polygenic risk scores for common conditions in adults and children. eMERGE researchers aim to learn about how people’s family history and genetic makeup affect their risk of developing common conditions such as heart disease, diabetes, and cancer, and about how to use this information to help them reduce their risk. The study will recruit 25,000 participants from around the country, including groups who are underrepresented in biomedical research.

Each participant will provide a biospecimen for genetic testing and fill out surveys about personal and family health history. Participants will receive a Genome Informed Risk Assessment (GIRA) report that includes their estimated risk for common conditions based on genetic testing results, clinical variables, and family history. The GIRA report will be uploaded to the participant's electronic health record and is meant to help participants and providers interpret risk for common conditions. A subset of participants will receive their results from a member of the study team in-person or by a virtual appointment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults, 18-75 years of age.
  • Children 3 to < 18 years of age.
  • Able to read or understand English or Spanish.
  • Able to provide a healthcare provider or clinician to receive results.
  • Willing to accept GIRA report.

Exclusion Criteria:

  • Inability to provide consent.
  • Transplant (solid organ or bone marrow) or transfusion within 8 weeks.
  • Research staff and investigators in eMERGE.
  • Unable to provide a HCP to receive results.
  • Not a patient at parent institution.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Iftikhar Kullo, M.D.

Open for enrollment

Contact information:

RST Atherosclerosis and Lipid Genomics Laboratory

RSTKulloLab@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20534585

Mayo Clinic Footer